FDA Approves IONIS Drug Zanvastro for Alexander Disease

Ionis wins first-ever approval for a disease-modifying Alexander disease therapy, plus a rare pediatric disease priority review voucher.

Share
Ionis' RNA-targeted therapy targets excess GFAP protein in the brain.
Ionis' RNA-targeted therapy targets excess GFAP protein in the brain. Foto: Ionis Pharmaceuticals · Public domain via Wikimedia Commons